Accelerating Drug Development & Improving Patient Outcomes

Dana-Farber is a global leader in drug discovery, playing a critical role in the development of more than half of all cancer drugs approved by the FDA in the past 5 years. Yet many cancer-causing proteins are not susceptible to drugs designed in the usual way. Hear more from Eric Fischer, PhD, Director of the Chemical Biology Program, and Catherine Wu, MD, Chief of the Division of Stem Cell Transplantation and Cellular Therapies, as they discuss how Dana-Farber’s pursuit of next-generation cancer drugs is expanding treatment options and offering hope to adults and children with rare, recurrent or difficult-to-treat cancers.

Give Now

Thank you for your interest in learning more about The Dana-Farber Campaign. You have been added to our email list and will receive updates on ways to join us in defying cancer. You can unsubscribe at any time.

There has been an issue submitting your request. Please try again.

Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and a federally designated Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries throughout the world. About Our Patient Stories: Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

At Dana-Farber we are committed to an inclusive community where human differences are valued and celebrated, and where all are welcome. We work every day to create an innovative, caring, and inclusive environment where each patient, family, and staff member feels valued and respected.